Better safety and quality of life in patients with chronic hepatitis B than in patients with chronic hepatitis C when treated with peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy

被引：0
|
作者：
Marcellin, P
Lau, G
Piratvisuth, T
Luo, KX
Bonino, F
Thongasawat, S
Cooksley, G
Hadziyannis, S
Chutaputti, A
Lu, ZM
Fried, M
Chow, WC
Yurdaydin, C
Berg, T
Pluck, N
机构：
[1] Hop Beaujon, Clichy, France
[2] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[3] Songklanakarin Hosp, Songkhla, Thailand
[4] Nangfang Hosp, Guangzhou, Peoples R China
[5] IRCCS Osped Maggiore, Sci Direct, Milan, Italy
[6] Chiang Mai Univ, Chiang Mai 50000, Thailand
[7] Univ Queensland, Royal Brisbane Hosp, Herston, Qld, Australia
[8] H Dynant Hosp, Athens, Greece
[9] Pramongkutklao Hosp, Bangkok, Thailand
[10] Ruijin Hosp, Shanghai, Peoples R China
[11] Univ N Carolina, Chapel Hill, NC USA
[12] Singapore Gen Hosp, Singapore 0316, Singapore
[13] Ankara Univ, TR-06100 Ankara, Turkey
[14] Charite Humboldt Univ Berlin, Berlin, Germany
[15] Roche, Welwyn Garden City, England
来源：
HEPATOLOGY | 2004年 / 40卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：668A / 668A
页数：1
相关论文
共 50 条
  • [1] Peginterferion alfa-2a (40KD) (Pegasys®) for the treatment of patients with chronic hepatitis C
    Ferenci, P
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2003, 57 (07) : 610 - 615
  • [2] Effect of ethnicity on the pharmacokinetics of ribavirin (COPEGUS®) and peginterferon alfa-2a (40kd) (PEGASYS®) in patients with chronic hepatitis C
    Brennan, B
    Morrison, R
    Hagedorn, C
    Marbury, TC
    Sulkowski, M
    Grippo, J
    Gries, JM
    HEPATOLOGY, 2005, 42 (04) : 652A - 653A
  • [3] Histologic benefit of peginterferon alfa-2a (40kd) (Pegasys®) monotherapy in patients with advanced fibrosis or cirrhosis due to chronic hepatitis C.
    Everson, G
    Heathcote, J
    Pappas, SC
    Govindarajan, S
    Lentz, E
    Lopez-Talavera, JC
    HEPATOLOGY, 2004, 40 (04) : 316A - 316A
  • [4] Peginterferon alfa-2a (40KD) (Pegasys®) and ribavirin is an efficacious and safe treatment for chronic hepatitis C in patients with cirrhosis.
    Marcellin, P
    Brillanti, S
    Cheínquer, H
    Cooksley, WGE
    Shiffmann, ML
    Schmidt, WE
    Brunda, M
    HEPATOLOGY, 2002, 36 (04) : 576A - 576A
  • [5] Efficacy and Safety of Peginterferon alfa-2a (40KD) in HBeAg-positive Chronic Hepatitis B Patients
    Caruntu, Florin Alexandru
    Streinu-Cercel, Adrian
    Gheorghe, Liliana Simona
    Grigorescu, Mircea
    Sporea, Ioan
    Stanciu, Carol
    Andronescu, Dan
    Voinea, Florea
    Diculescu, Mircea
    Oproiu, Alexandru
    Voiosu, Rodu
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2009, 18 (04) : 425 - 431
  • [6] Pharmacokinetics of peginterferon ALFA-2A (40KD, PEGASYS) compared to peginterferon ALFA-2B (12KD, pegintron) in naive patients with chronic hepatitis C (CHC)
    Bruno, R
    Sacchi, P
    Ciappina, V
    Maffezzini, E
    Patruno, SFA
    Zocchetti, C
    Filice, G
    JOURNAL OF HEPATOLOGY, 2003, 38 : 129 - 130
  • [7] ALT flares and sustained ALT response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) (PEGASYS®), peginterferon alfa-2a (40KD) plus lamivudine or lamivudine alone
    Piratvisuth, T
    Marcellin, P
    Lau, G
    Bonino, F
    Farci, P
    Hadziyannis, S
    Jin, R
    Lu, ZM
    Germanidis, G
    Yurdaydin, C
    Diago, M
    Gurel, S
    Lai, MY
    Button, P
    Why, RD
    Pluck, N
    HEPATOLOGY, 2004, 40 (04) : 656A - 657A
  • [8] The safety, efficacy and pharmacokinetics of peginterferon alfa-2a (40KD) in children with chronic hepatitis C
    Schwarz, KB
    Mohan, P
    Narkewicz, M
    Molleston, JP
    Te, HS
    Hu, S
    Sheridan, S
    Lamb, M
    Pappas, SC
    Harb, G
    GASTROENTEROLOGY, 2003, 124 (04) : A700 - A700
  • [9] Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin
    Foster, Graham R.
    Fried, Michael W.
    Hadziyannis, Stephanos J.
    Messinger, Diethelm
    Freivogel, Klaus
    Weiland, Ola
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2007, 42 (02) : 247 - 255
  • [10] Optimized virological response in genotype 4 chronic hepatitis C patients treated with peginterferon alfa-2A (40KD) (PEGASYS®) in combination with ribavirin (RBV).
    Diago, M
    Hadziyannis, SJ
    Dunant, H
    Bodenheimer, H
    Hassanein, T
    Uchman, S
    Marcellin, P
    Ramadori, G
    Delwaide, J
    Sedarati, F
    HEPATOLOGY, 2002, 36 (04) : 364A - 364A
12345